Impact of mtor-i on fertility and pregnancy: State of the art and review of the literature

Expert Review of Clinical Immunology

Volumn 9, Issue 8, 2013, Pages 781-789

  Framarino Dei Malatesta, Marialuisa ^a   Derme, Martina ^a   Manzia, Tommaso M ^b   Iaria, Giuseppe ^b   De Luca, Linda ^c   Fazzolari, Laura ^a   Napoli, Angela ^a   Berloco, Pasquale ^a   Patel, Timil ^d   Orlando, Giuseppe ^d   Tisone, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

fertility; immunosuppression; kidney transplant8mTORi; pregnancy

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; FOLLITROPIN; IMMUNOSUPPRESSIVE AGENT; LUTEINIZING HORMONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TACROLIMUS; TESTOSTERONE;

ASTHENOSPERMIA; AZOOSPERMIA; DRUG CONTRAINDICATION; DRUG SUBSTITUTION; FERTILITY; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GONAD DYSFUNCTION; HORMONE METABOLISM; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; NONHUMAN; OLIGOSPERMIA; PREGNANCY; REVIEW; SEXUAL FUNCTION; SIDE EFFECT;

ANIMALS; CELL CYCLE; FEMALE; FERTILITY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY OF LIFE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84887830744     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.824243     Document Type: Review

References (56)

1. Iaria G, Pisani F, Iorio B et al. Long-term results of kidney transplantation with cyclosporine-and everolimus-based immunosuppression. Transplant. Proc. 38(4), 1018-1019 (2006).
2. Salvadori M, Scolari MP, Bertoni E et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 88(10), 1194-1202 (2009).
3. Iaria G, Anselmo A, De Luca L et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant. Proc. 39(6), 2036-2037 (2007).
4. Manuelli M, De Luca L, Iaria G et al. Conversion to rapamycin immunosuppres sion for malignancy after kidney transplantation. Transplant. Proc. 42(4), 1314-1316 (2010).
5. Manzia TM, Bellini MI, Corona L et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl. Int. 24(8), e69-70 (2011).
6. White PS, Swindells DCN. Acta Crytallogr. A (Volume 37). C75 (1981).
7. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant. Proc. 30(5), 2192-2194 (1998).
8. Bererhi L, Flamant M, Martinez F, Karras A, Thervet E, Legendre C. Rapamycin induced oligospermia. Transplantation 76(5), 885-886 (2003).
9. Kaczmarek I, Groetzner J, Adamidis I et al. Sirolimus impairs gonadal function in heart transplant recipients. Am. J. Transplant. 4(7), 1084-1088 (2004).
10. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am. J. Transplant. 4(1), 130-131 (2004).
11. Tondolo V, Citterio F, Panocchia N et al. Gonadal function and immunosuppressive therapy after renal transplantation. Transplant. Proc. 37(4), 1915-1917 (2005).
12. Lee S, Coco M, Greenstein SM, Schechner RS, Tellis VA, Glicklich DG. The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin. Transplant. 19(2), 162-167 (2005).
13. Skrzypek J, Krause W. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment. Andrologia 39(5), 198-199 (2007).
14. Deutsch MA, Kaczmarek I, Huber S et al. Sirolimus associated infertility: case report and literature review of possible mechanisms. Am. J. Transplant. 7(10), 2414-2421 (2007).
15. Zuber J, Anglicheau D, Elie C et al. Sirolimus may reduce fertility in male renal transplant recipients. Am. J. Transplant. 8(7), 1471-1479 (2008).
16. Boobes Y. Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int. Urol. Nephrol. 42(2), 493-498 (2010).
17. Rovira J, Diekmann F, Ramírez-Bajo MJ, Bañón-Maneus E, Moya-Rull D, Campistol JM. Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation 93(9), 874-879 (2012).
18. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J. mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS ONE 6(7), e21415 (2011).
19. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipients. IV.10. Pregnancy in renal transplant recipients. Nephrol. Dial. Transplant. 17(Suppl 4), 50-55 (2002).
20. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet. Gynecol. 103(5 Pt 2), 1091-1094 (2004).
21. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82(12), 1698-1702 (2006).
22. Perez-Aytes A, Ledo A, Boso V et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am. J. Med. Genet. A. 146A(1), 1-7 (2008).
23. Framarino dei Malatesta M, Rocca B, Gentile T et al. A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. Transpl. Proc. 41(4), 1407-1409 (2009).
24. Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum. Reprod. Update. 5(5), 535-545 (1999).
25. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit upregulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J. Biol. Chem. 275(33), 25572-25576 (2000).
26. Walensky LD, Dawson TM, Steiner JP et al. The 12 kD FK 506 binding protein FKBP12 is released in the male reproductive tract and stimulates sperm motility. Mol. Med. 4(8), 502-514 (1998).
27. Sosnowski R, Mellon PL, Lawson MA. Activation of translation in pituitary gonadotrope cells by gonadotropinreleasing hormone. Mol. Endocrinol. 14(11), 1811-1819 (2000).
28. Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z et al. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant. Proc. 36(10), 3232-3233 (2004).
29. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82(12), 1698-1702 (2006).
30. Guardia O, Rial MC, Casadei D. Pregnancy under sirolimus-based immunosuppression. Transplantation 81(4), 636 (2006).
31. Chu SH, Liu KL, Chiang YS, Wang HH, Lai PC. Sirolimus used during pregnancy in a living related renal transplant recipient: a case report. Transpl. Proc. 40(7), 2446-2448 (2008).
32. Framarino dei Malatesta M, Corona LE, De Luca L et al. Succesfull pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation 91(9), 69-71 (2011).
33. Veroux M, Corona D, Veroux P. Pregnancy under everolimus-based immunosuppression. Transpl. Int. 24(12), e115-117 (2011).
34. Carta P, Caroti L, Zanazzi M. Pregnancy in a kidney transplant patient treated with everolimus. Am. J. Kidney. Dis. 60(2), 329 (2012).
35. Lager S, Powell TL. Regulation of nutrient transport across the placenta. J. Pregnancy. doi:10.1155/2012/179827 (2012) (Epub ahead of print).
36. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renaltransplantation. Transplantation 66(8), 1040-1046 (1998).
37. Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 72(7), 1244-1250 (2001).
38. Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 43(8), 1170-1180 (2002).
39. Houde VP, Brûlé S, Festuccia WT et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59(6), 1338-1348 (2010).
40. Claes K, Meier-Kriesche HU, Schold JD et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol. Dial. Transplant 27(2), 850-857 (2012).
41. Vigano M, Tuzcu M, Benza R et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J. Heart Lung Transplant 26(6), 584-592 (2007).
42. Zortress® , package insert. Novartis Pharmaceuticals, NJ, USA.
43. Baumann MU, Deborde S, Illsley NP. Placental glucose transfer and fetal growth. Endocrine. 19(1), 13-22 (2002).
44. Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signalling. Am. J. Physiol. Cell Physiol. 297(3), C723-731 (2009).
45. Blagosklonny MV. Rapamycin-induced glucose intolerance: hunger or starvation diabetes. Cell Cycle. 10(24), 4217-4224 (2011).
46. Lamming DW, Ye L, Katajisto P et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335(6076), 1638-1643 (2012).
47. Pereira MJ, Palming J, Rizell M et al. mTOR inhibition with rapamycin causes impaired insulin signaling and glucose uptake in human subcutaneous and omental adipocytes. Mol. Cell. Endocrinol. 355(1), 96-105 (2012).
48. Nash B, Citterio F. Wound healing complications and the use of Mammalian Target of Rapamycin Inhibitors in kidney transplantation: a critical review of the literature. Transplantatio 94(6), 547-561 (2012).
49. Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod. Sci. 16(5), 431-437 (2009).
50. Srivastava A, Muruganandham K, Vinodh PB et al. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs m-TOR inhibitors. Int. Urol. Nephrol. 42(2), 279-284 (2010).
51. Kuppahally S, Al-Khaldi A, Weisshaar D et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetilbased regimen in cardiac transplant recipients. Am. J. Transplant. 6(5 Pt 1), 986-992 (2006).
52. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant 6(6), 1377-1386 (2006).
53. Dean PG, Lund WJ, Larson TS et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77(10), 1555-1561 (2004).
54. Flechner SM, Zhou L, Derweesh I et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidneytransplant recipients. Transplantation 76(12), 1729-1734 (2003).
55. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am. J. Transplant. 3(9), 1128-1134 (2003).
56. Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod. Sci. 16(5), 431-437 (2009).